Chordoma Disease- Latest Trends and Insights

2018-05-21 16:52:04

According to a new report published by Reports Monitor titled, “ Global Chordoma Disease Market, Growth Opportunities, Innovations and Forecast, 2018-2025,” the global chordoma disease market was valued at XX million in 2018, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2018 to 2025.

Chordoma is a rare type of primary bone cancer that is typically malignant in nature. This type of tumor occurs mostly at the skull base or along the spine. These tumors are formed from small fragments of embryonic cells that accumulate into the disks of the spinal column. 

The prevalence is found to be twice in men in comparison with women. Moreover, most of the tumor cases occur between the age group of 50 to 70 years.  Tumor immunotherapy has become the trend of the future, which is more excellent in clinical efficacy. It significantly improved the overall survival of patients in the approved indications. The increasing occurrence of bone cancer along with growing government initiatives for bone cancer awareness and aging population globally are the major factors expected to fuel the global chordoma disease market over the forecast period. The high prevalence of chondroid chordomas is the major hurdle in the market growth. 

Download Sample PDF:

The preferred surgical treatment for chordomas of the skull base is Endoscopic Endonasal Approach developed by UPMC. This minimally insidious method uses nasal cavities as a corridor to reach the inoperable tumors. The benefits of EEA surgeries include no incisions to heal, no disfigurement, and faster recovery. Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market.

The global chordoma disease market is segmented based on diagnosis, treatment, and end-user. On the basis of diagnosis, the market is segmented as blood tests, biopsy, imaging, and others. The imaging segment is further divided as Computed Tomography (CT) scan, x-ray, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) scanning, and bone scan. Based on treatment, the market is segmented into surgical treatments, radiosurgery, targeted therapy, chemotherapy, radiation therapy, cryosurgery, and others. The surgery segment is further divided into spinal chordoma, skull base chordoma, radical resections, sacral chordoma and others. The chemotherapy segment is segmented into doxorubicin, methotrexate, and others. Moreover, the targeted therapy segment is segmented into erlotinib, bevacizumab,  and others. Additionally, based on end-user, the global chordoma disease market is segmented into cancer care centers, hospitals, clinics, and others.

The global chordoma disease market consists of regions, namely North America, Europe, Asia Pacific, South America, Middle East & Africa. The Americas region is predicted to have largest market share of the global chordoma disease market owing to the high prevalence of aging population and bone cancer in the region. The European chordoma disease market is also anticipated to emerge as the largest market owing to the development of the medical and pharmaceutical industries. The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region.The Middle Eastern region is predicted to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.

The key vendors in this market are: 

Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), GlaxoSmithKline plc (UK), AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France)

About Us:

We at Garner provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.

Contact Us:

Mr. Kevin Thomas


+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]

Related Press Releases